Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CD69 | Q07108 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 3/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216951 | 0.85 | MAPT (0.50) | TSHRSMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL3410954 | 0.85 | MAPT (0.48) | TSHRSMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL29503795 | 0.83 | MAPT (0.43) | TSHRSMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL503651 | 0.82 | SMN1; SMN2 (0.70) | TSHRSMN1; SMN2MAPTALDH1A1KMT2A | |
| SCHEMBL6642984 | 0.82 | TSHR (0.44) | TSHRSMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL8063168 | 0.82 | MAPT (0.48) | TSHRSMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL26623341 | 0.82 | MAPT (0.48) | TSHRSMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL12745899 | 0.81 | KDM4E (0.48) | TSHRSMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL19555342 | 0.79 | ALOX15 (0.52) | TSHRSMN1; SMN2MAPTALDH1A1KMT2A | |
| SCHEMBL22308325 | 0.79 | MAPT (0.49) | TSHRSMN1; SMN2MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023215559-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215559-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-7692038-B2 | Crystalline forms | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692038-B2 | Crystalline forms | PFIZER, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080249031-A1 | Of (3S)-3-[N (N'-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-oxopentanoic acid; liver fibrosis | PFIZER, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080249031-A1 | Of (3S)-3-[N (N'-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-oxopentanoic acid; liver fibrosis | PFIZER, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249031-A1 | Of (3S)-3-[N (N'-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-oxopentanoic acid; liver fibrosis | OTC, PYGL, SLC10A1 | TSHR 2921/4885SMN1; SMN2 2956/4885MAPT 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.